Inactive Instrument

News India Globalization Capital, Inc. Nyse

Equities

US45408X3089

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

IGC-AD1'S Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two	Apr. 17	AQ
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two	Apr. 16	BU
IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer?S At Week Two Compared to Placebo	Apr. 16	CI
IGC Pharma Adds Advisor in Artificial Intelligence	Apr. 09	BU
IGC Pharma : Announces Positive Interim Results for IGC-AD1 in - Form 8-K	Apr. 05	PU
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock	Mar. 26	BU
Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	Mar. 22	MT
Aurora Cannabis, Canopy Growth Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	Mar. 22	MT
IGC Pharma : Material Agreement - Form 8-K	Mar. 22	PU
IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited	Mar. 21	CI
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation	Mar. 21	AQ
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation	Mar. 20	BU
IGC Pharma, Inc Announces the Results of an Interim Analysis of its Ongoing Phase 2 Trial Investigating IGC-Ad1 as Treatment for Agitation in Dementia from Alzheimer?s Disease	Mar. 20	CI
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024	Mar. 20	BU
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline	Mar. 12	BU
Igc Pharma, Inc. Appoints Terry Lierman as Independent Director to Its Board of Directors	Mar. 12	CI
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model	Feb. 28	BU
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target	Feb. 23	BU
IGC Pharma Reports Third Quarter Fiscal 2024 Results	Feb. 16	BU
IGC Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News India Globalization Capital, Inc. Nyse

Equities

US45408X3089

Summary

Filters